Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | PKM | P14618 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27370258 | 0.83 | PDE10A (0.51) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL2222503 | 0.81 | MEN1 (0.56) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL11016312 | 0.80 | MEN1 (0.63) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL29431832 | 0.78 | MEN1 (0.51) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL28729479 | 0.78 | MEN1 (0.51) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL8692084 | 0.78 | MAPT (0.52) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL6941009 | 0.78 | MEN1 (0.57) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL1620133 | 0.77 | MAPT (0.57) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL4034758 | 0.77 | NPC1 (0.62) | MEN1KMT2AL3MBTL1MAPTNPC1 | |
| SCHEMBL12890441 | 0.77 | KMT2A (0.52) | MEN1KMT2AL3MBTL1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | disclosed |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | ABS DEVELOPMENT 1, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | ABS DEVELOPMENT 1, INC. (US) | 2023-06-27 | — | — | US | disclosed |
| EP-3083619-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES LLC (US) | 2021-11-03 | — | — | EP | disclosed |
| US-20200109143-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2020-04-09 | — | — | US | disclosed |
| US-10590127-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-06-11 | — | — | US | disclosed |
| US-20160296501-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-20160296501-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| WO-2015095128-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095128-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2015-06-25 | — | — | WO | disclosed |
| US-8232406-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | DONG WHA PHARM. CO., LTD. (KR) | 2011-12-15 | — | — | US | disclosed |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7872031-B2 | c-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2004625-B1 | C-MET PROTEIN KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | VERTEX PHARMA (US) | 2009-12-30 | — | — | EP | disclosed |
| US-20070254868-A1 | C-MET protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306606-A1 | NOVEL 2,6-SUBSTITUTED-3-NITROPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | NOS3, PTMS, NOS2 | MEN1 2648/4885KMT2A 1765/4885L3MBTL1 4883/4885 |
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | MEN1 3309/4885KMT2A 2807/4885L3MBTL1 3916/4885 |
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | MEN1 3309/4885KMT2A 2807/4885L3MBTL1 3916/4885 |
| US-20110059936-A1 | C-MET PROTEIN KINASE INHIBITORS | MET, PRKCH, ABL1 | MEN1 402/4885KMT2A 1014/4885L3MBTL1 1318/4885 |
| US-10590127-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | MEN1 3819/4885KMT2A 3309/4885L3MBTL1 2847/4885 |
| US-20070254868-A1 | C-MET protein kinase inhibitors | MET, PRKCH, ABL1 | MEN1 402/4885KMT2A 1014/4885L3MBTL1 1318/4885 |
| US-20200109143-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | MEN1 3309/4885KMT2A 2807/4885L3MBTL1 3916/4885 |
| US-20160296501-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | MEN1 3819/4885KMT2A 3309/4885L3MBTL1 2847/4885 |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | MEN1 3309/4885KMT2A 2807/4885L3MBTL1 3916/4885 |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | MEN1 3309/4885KMT2A 2807/4885L3MBTL1 3916/4885 |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | MEN1 3309/4885KMT2A 2807/4885L3MBTL1 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.